Lonza has opened a new 300,000-square-foot dedicated cell and gene therapy manufacturing facility in Pearland, Texas, part of the Greater Houston area.
Lonza Houston will serve as a centre of excellence for cell and gene-therapy process development from concept through preclinical, clinical, and commercialization. The Lonza Houston Center of Excellence is already operational and manufacturing for several customers. Lonza is recruiting employees for this facility and says it will have more than 200 full-time staff, including scientists, engineers, MBAs, and biotechnology professionals by the end of 2018.
The Lonza Houston Centre of Excellence is one of four centres of excellence in cell and gene therapy for the company. The Lonza sites in Pearland, Texas and Geleen/Maastricht, The Netherlands will provide a fully integrated range of cell and gene therapy services, including process and analytical development, clinical product supply, and commercial product supply. Lonza’s sites in Portsmouth, New Hampshire and Singapore will serve both as clinical and commercial manufacturing sites.